Leukemia Clinical Trials in Cleveland

Showing 1081-1100 of 1,477 trials

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

NCT01408043

This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.

Adult Acute Lymphoblastic Leukemia in RemissionAdult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-cell Lymphoma+31 more

Case Comprehensive Cancer Center25 participantsStarted Oct 2011

Cleveland, Ohio, United States

COMPLETEDPhase 3< 1 mile

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

NCT00693992

This randomized phase III trial studies sunitinib malate to see how well it works when given as maintenance therapy (meaning it is approved for treatment after chemotherapy) in patients with stage IIIB-IV non-small cell lung cancer who have responded to prior treatment with combination chemotherapy. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether sunitinib malate is effective in helping tumors continue to shrink or stop growing.

Stage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Non-Small Cell Lung Cancer AJCC v7

National Cancer Institute (NCI)210 participantsStarted Jun 2008

Anniston, Alabama, United States • Mobile, Alabama, United States • Little Rock, Arkansas, United States +481 more locations

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Leukemia Trials in Other Cities

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Observational Study of Surgical Treatment of Necrotizing Enterocolotis

Early Diagnosis of Candidiasis in Premature Infants

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Immunogenicity of PCV-7 Vaccine in VLBW Infants

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Frequency of Screening and SBT Technique Trial

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

A Study for Patients With Acute Leukemia

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Comparability and Standardization of Controlled Allergen Challenge Facilities

Other Conditions in Cleveland